|
1
|
Juliusson G and Hough R: Leukemia. Prog
Tumor Res. 43:87–100. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alsobhi E, Farahat F, Daghistani M, Awad
K, Al-Zahran O, Al-Saiari A and Koshak F: Overall survival of adult
acute myeloid leukemia based on cytogenetic and molecular
abnormalities during 5 years in a single center study. Saudi Med J.
40:1171–1176. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Schubert D: A brief history of adherons:
The discovery of brain exosomes. Int J Mol Sci.
21(7673)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Johnstone RM, Adam M, Hammond JR, Orr L
and Turbide C: Vesicle formation during reticulocyte maturation.
Association of plasma membrane activities with released vesicles
(exosomes). J Biol Chem. 262:9412–9420. 1987.PubMed/NCBI
|
|
5
|
Keller S, Sanderson MP, Stoeck A and
Altevogt P: Exosomes: From biogenesis and secretion to biological
function. Immunol Lett. 107:102–108. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Simpson RJ, Jensen SS and Lim JW:
Proteomic profiling of exosomes: Current perspectives. Proteomics.
8:4083–4099. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Théry C, Zitvogel L and Amigorena S:
Exosomes: Composition, biogenesis and function. Nat Rev Immunol.
2:569–579. 2002.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Skog J, Würdinger T, van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Mardani R, Jafari Najaf Abadi MH, Motieian
M, Taghizadeh-Boroujeni S, Bayat A, Farsinezhad A, Gheibi HS,
Motieian M and Pourghadamyari H: MicroRNA in leukemia: Tumor
suppressors and oncogenes with prognostic potential. J Cell
Physiol. 234:8465–8486. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu J, Ren L, Li S, Li W, Zheng X, Yang Y,
Fu W, Yi J, Wang J and Du G: The biology, function, and
applications of exosomes in cancer. Acta Pharm Sin B. 11:2783–2797.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cheng L and Hill AF: Therapeutically
harnessing extracellular vesicles. Nat Rev Drug Discov. 21:379–399.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
De Toro J, Herschlik L, Waldner C and
Mongini C: Emerging roles of exosomes in normal and pathological
conditions: New insights for diagnosis and therapeutic
applications. Front Immunol. 6(203)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang L and Yu D: Exosomes in cancer
development, metastasis, and immunity. Biochim Biophys Acta Rev
Cancer. 1871:455–468. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lobb RJ, Becker M, Wen SW, Wong CS,
Wiegmans AP, Leimgruber A and Möller A: Optimized exosome isolation
protocol for cell culture supernatant and human plasma. J Extracell
Vesicles. 4(27031)2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Khatun Z, Bhat A, Sharma S and Sharma A:
Elucidating diversity of exosomes: Biophysical and molecular
characterization methods. Nanomedicine (Lond). 11:2359–2377.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guo S, Xu J, Estell AP, Ivory CF, Du D,
Lin Y and Dong WJ: Paper-based ITP technology: An application to
specific cancer-derived exosome detection and analysis. Biosens
Bioelectron. 164(112292)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Agarwal P and Bhatia R: Influence of bone
marrow microenvironment on leukemic stem cells: Breaking up an
intimate relationship. Adv Cancer Res. 127:227–252. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sharma A, Khatun Z and Shiras A: Tumor
exosomes: Cellular postmen of cancer diagnosis and personalized
therapy. Nanomedicine (Lond). 11:421–437. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tan Z, Kan C, Wong M, Sun M, Liu Y, Yang
F, Wang S and Zheng H: Regulation of malignant myeloid leukemia by
mesenchymal stem cells. Front Cell Dev Biol.
10(857045)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Boyiadzis M and Whiteside TL: Exosomes in
acute myeloid leukemia inhibit hematopoiesis. Curr Opin Hematol.
25:279–284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Huan J, Hornick NI, Shurtleff MJ, Skinner
AM, Goloviznina NA, Roberts CT Jr and Kurre P: RNA trafficking by
acute myelogenous leukemia exosomes. Cancer Res. 73:918–929.
2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huan J, Hornick NI, Goloviznina NA,
Kamimae-Lanning AN, David LL, Wilmarth PA, Mori T, Chevillet JR,
Narla A, Roberts CT Jr, et al: Coordinate regulation of residual
bone marrow function by paracrine trafficking of AML exosomes.
Leukemia. 29:2285–2295. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kumar B, Garcia M, Weng L, Jung X,
Murakami JL, Hu X, McDonald T, Lin A, Kumar AR, DiGiusto DL, et al:
Acute myeloid leukemia transforms the bone marrow niche into a
leukemia-permissive microenvironment through exosome secretion.
Leukemia. 32:575–587. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hornick NI, Doron B, Abdelhamed S, Huan J,
Harrington CA, Shen R, Cambronne XA, Chakkaramakkil VS and Kurre P:
AML suppresses hematopoiesis by releasing exosomes that contain
microRNAs targeting c-MYB. Sci Signal. 9(ra88)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhao C, Du F, Zhao Y, Wang S and Qi L:
Acute myeloid leukemia cells secrete microRNA-4532-containing
exosomes to mediate normal hematopoiesis in hematopoietic stem
cells by activating the LDOC1-dependent STAT3 signaling pathway.
Stem Cell Res Ther. 10(384)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yoshida M, Horiguchi H, Kikuchi S, Iyama
S, Ikeda H, Goto A, Kawano Y, Murase K, Takada K, Miyanishi K, et
al: miR-7977 inhibits the Hippo-YAP signaling pathway in bone
marrow mesenchymal stromal cells. PLoS One.
14(e213220)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang L, Khadka B, Wu J, Feng Y, Long B,
Xiao R and Liu J: Bone marrow mesenchymal stem cells-derived
exosomal miR-425-5p inhibits acute myeloid leukemia cell
proliferation, apoptosis, invasion and migration by targeting WTAP.
Onco Targets Ther. 14:4901–4914. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chiarini F, Lonetti A, Evangelisti C,
Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM,
Mccubrey JA and Martelli AM: Advances in understanding the acute
lymphoblastic leukemia bone marrow microenvironment: From biology
to therapeutic targeting. Biochim Biophys Acta. 1863:449–463.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Rios de Los Rios J, Enciso J,
Vilchis-Ordoñez A, Vázquez-Ramírez R, Ramirez-Ramirez D, Balandrán
JC, Rodríguez-Martínez A, Ruiz-Tachiquín M, Pompa-Mera E, Mendoza
L, et al: Acute lymphoblastic leukemia-secreted miRNAs induce a
proinflammatory microenvironment and promote the activation of
hematopoietic progenitors. J Leukoc Biol. 112:31–45.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yang Y, Li J and Geng Y: Exosomes derived
from chronic lymphocytic leukaemia cells transfer miR-146a to
induce the transition of mesenchymal stromal cells into
cancer-associated fibroblasts. J Biochem. 168:491–498.
2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Paggetti J, Haderk F, Seiffert M, Janji B,
Distler U, Ammerlaan W, Kim YJ, Adam J, Lichter P, Solary E, et al:
Exosomes released by chronic lymphocytic leukemia cells induce the
transition of stromal cells into cancer-associated fibroblasts.
Blood. 126:1106–1117. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yeh YY, Ozer HG, Lehman AM, Maddocks K, Yu
L, Johnson AJ and Byrd JC: Characterization of CLL exosomes reveals
a distinct microRNA signature and enhanced secretion by activation
of BCR signaling. Blood. 125:3297–3305. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Prieto D, Sotelo N, Seija N, Sernbo S,
Abreu C, Durán R, Gil M, Sicco E, Irigoin V, Oliver C, et al:
S100-A9 protein in exosomes from chronic lymphocytic leukemia cells
promotes NF-κB activity during disease progression. Blood.
130:777–788. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Corrado C, Raimondo S, Saieva L, Flugy AM,
De Leo G and Alessandro R: Exosome-mediated crosstalk between
chronic myelogenous leukemia cells and human bone marrow stromal
cells triggers an interleukin 8-dependent survival of leukemia
cells. Cancer Lett. 348:71–76. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Taverna S, Amodeo V, Saieva L, Russo A,
Giallombardo M, De Leo G and Alessandro R: Exosomal shuttling of
miR-126 in endothelial cells modulates adhesive and migratory
abilities of chronic myelogenous leukemia cells. Mol Cancer.
13(169)2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jiang YH, Liu J, Lin J, Li SQ, Xu YM, Min
QH, Zhong QH, Sun F, Li J, You XH, et al: K562 cell-derived
exosomes suppress the adhesive function of bone marrow mesenchymal
stem cells via delivery of miR-711. Biochem Biophys Res Commun.
521:584–589. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang Y, He H, He J, Gu X, Hu P, Zuo R and
Sa Y: Hyperleukocytic acute leukemia circulating exosomes regulate
HSCs and BM-MSCs. J Healthc Eng. 2021(9457070)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Gao X, Wan Z, Wei M, Dong Y, Zhao Y, Chen
X, Li Z, Qin W, Yang G and Liu L: Chronic myelogenous leukemia
cells remodel the bone marrow niche via exosome-mediated transfer
of miR-320. Theranostics. 9:5642–5656. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jafarzadeh N, Gholampour MA, Alivand MR,
Kavousi S, Arzi L, Rad F, Sadeghizadeh M and Pornour M: CML derived
exosomes promote tumor favorable functional performance in T cells.
BMC Cancer. 21(1002)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wan Z, Chen X, Gao X, Dong Y, Zhao Y, Wei
M, Fan W, Yang G and Liu L: Chronic myeloid leukemia-derived
exosomes attenuate adipogenesis of adipose derived mesenchymal stem
cells via transporting miR-92a-3p. J Cell Physiol. 234:21274–21283.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang D, Ming X, Xu J and Xiao Y:
Circ_0009910 shuttled by exosomes regulates proliferation, cell
cycle and apoptosis of acute myeloid leukemia cells by regulating
miR-5195-3p/GRB10 axis. Hematol Oncol. 39:390–400. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cheng H, Ding J, Tang G, Huang A, Gao L,
Yang J and Chen L: Human mesenchymal stem cells derived exosomes
inhibit the growth of acute myeloid leukemia cells via regulating
miR-23b-5p/TRIM14 pathway. Mol Med. 27(128)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jiang D, Wu X, Sun X, Tan W, Dai X, Xie Y,
Du A and Zhao Q: Bone mesenchymal stem cell-derived exosomal
microRNA-7-5p inhibits progression of acute myeloid leukemia by
targeting OSBPL11. J Nanobiotechnology. 20(29)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang F, Lu Y, Wang M, Zhu J, Li J, Zhang
P, Yuan Y and Zhu F: Exosomes derived from human bone marrow
mesenchymal stem cells transfer miR-222-3p to suppress acute
myeloid leukemia cell proliferation by targeting IRF2/INPP4B. Mol
Cell Probes. 51(101513)2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yan W, Song L, Wang H, Yang W, Hu L and
Yang Y: Extracellular vesicles carrying miRNA-181b-5p affects the
malignant progression of acute lymphoblastic leukemia. J Transl
Med. 19(511)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Raimondo S, Saieva L, Corrado C, Fontana
S, Flugy A, Rizzo A, De Leo G and Alessandro R: Chronic myeloid
leukemia-derived exosomes promote tumor growth through an autocrine
mechanism. Cell Commun Signal. 13(8)2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jaworski E, Narayanan A, Van Duyne R,
Shabbeer-Meyering S, Iordanskiy S, Saifuddin M, Das R, Afonso PV,
Sampey GC, Chung M, et al: Human T-lymphotropic virus type
1-infected cells secrete exosomes that contain Tax protein. J Biol
Chem. 289:22284–22305. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Haque S and Vaiselbuh SR: Silencing of
exosomal miR-181a reverses pediatric acute lymphocytic leukemia
cell proliferation. Pharmaceuticals (Basel). 13(241)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Aslan C, Maralbashi S, Salari F, Kahroba
H, Sigaroodi F, Kazemi T and Kharaziha P: Tumor-derived exosomes:
Implication in angiogenesis and antiangiogenesis cancer therapy. J
Cell Physiol. 234:16885–16903. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ludwig N and Whiteside TL: Potential roles
of tumor-derived exosomes in angiogenesis. Expert Opin Ther
Targets. 22:409–417. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Mineo M, Garfield SH, Taverna S, Flugy A,
De Leo G, Alessandro R and Kohn EC: Exosomes released by K562
chronic myeloid leukemia cells promote angiogenesis in a
Src-dependent fashion. Angiogenesis. 15:33–45. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Corrado C, Saieva L, Raimondo S, Santoro
A, De Leo G and Alessandro R: Chronic myelogenous leukaemia
exosomes modulate bone marrow microenvironment through activation
of epidermal growth factor receptor. J Cell Mol Med. 20:1829–1839.
2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Umezu T, Ohyashiki K, Kuroda M and
Ohyashiki JH: Leukemia cell to endothelial cell communication via
exosomal miRNAs. Oncogene. 32:2747–2755. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Roma-Rodrigues C, Fernandes AR and
Baptista PV: Counteracting the effect of leukemia exosomes by
antiangiogenic gold nanoparticles. Int J Nanomedicine.
14:6843–6854. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tadokoro H, Umezu T, Ohyashiki K, Hirano T
and Ohyashiki JH: Exosomes derived from hypoxic leukemia cells
enhance tube formation in endothelial cells. J Biol Chem.
288:34343–34351. 2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ohyashiki JH, Umezu T and Ohyashiki K:
Exosomes promote bone marrow angiogenesis in hematologic neoplasia:
The role of hypoxia. Curr Opin Hematol. 23:268–273. 2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Taverna S, Fontana S, Monteleone F, Pucci
M, Saieva L, De Caro V, Cardinale VG, Giallombardo M, Vicario E,
Rolfo C, et al: Curcumin modulates chronic myelogenous leukemia
exosomes composition and affects angiogenic phenotype via exosomal
miR-21. Oncotarget. 7:30420–30439. 2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wang B, Wang X, Hou D, Huang Q, Zhan W,
Chen C, Liu J, You R, Xie J, Chen P and Huang H: Exosomes derived
from acute myeloid leukemia cells promote chemoresistance by
enhancing glycolysis-mediated vascular remodeling. J Cell Physiol.
234:10602–10614. 2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ghosh AK, Secreto CR, Knox TR, Ding W,
Mukhopadhyay D and Kay NE: Circulating microvesicles in B-cell
chronic lymphocytic leukemia can stimulate marrow stromal cells:
Implications for disease progression. Blood. 115:1755–1764.
2010.PubMed/NCBI View Article : Google Scholar
|
|
60
|
El-Saghir J, Nassar F, Tawil N and
El-Sabban M: ATL-derived exosomes modulate mesenchymal stem cells:
Potential role in leukemia progression. Retrovirology.
13(73)2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Vago L and Gojo I: Immune escape and
immunotherapy of acute myeloid leukemia. J Clin Invest.
130:1552–1564. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Clayton A, Mitchell JP, Court J, Linnane
S, Mason MD and Tabi Z: Human tumor-derived exosomes down-modulate
NKG2D expression. J Immunol. 180:7249–7258. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Szczepanski MJ, Szajnik M, Welsh A,
Whiteside TL and Boyiadzis M: Blast-derived microvesicles in sera
from patients with acute myeloid leukemia suppress natural killer
cell function via membrane-associated transforming growth
factor-beta1. Haematologica. 96:1302–1309. 2011.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Haderk F, Schulz R, Iskar M, Cid LL, Worst
T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, et al:
Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci
Immunol. 2(eaah5509)2017.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chitadze G, Bhat J, Lettau M, Janssen O
and Kabelitz D: Generation of soluble NKG2D ligands: Proteolytic
cleavage, exosome secretion and functional implications. Scand J
Immunol. 78:120–129. 2013.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Whiteside TL: Immune modulation of T-cell
and NK (natural killer) cell activities by TEXs (tumour-derived
exosomes). Biochem Soc Trans. 41:245–251. 2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wieckowski EU, Visus C, Szajnik M,
Szczepanski MJ, Storkus WJ and Whiteside TL: Tumor-derived
microvesicles promote regulatory T cell expansion and induce
apoptosis in tumor-reactive activated CD8+ T lymphocytes. J
Immunol. 183:3720–3730. 2009.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Santos PM and Butterfield LH: Dendritic
cell-based cancer vaccines. J Immunol. 200:443–449. 2018.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Yin W, Ouyang S, Li Y, Xiao B and Yang H:
Immature dendritic cell-derived exosomes: A promise subcellular
vaccine for autoimmunity. Inflammation. 36:232–240. 2013.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Van Acker HH, Versteven M, Lichtenegger
FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF,
Berneman ZN and Anguille S: Dendritic cell-based immunotherapy of
acute myeloid leukemia. J Clin Med. 8(579)2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zhou J, Wang S, Sun K and Chng WJ: The
emerging roles of exosomes in leukemogeneis. Oncotarget.
7:50698–50707. 2016.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC,
Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, et al: Dendritic cell
biology and its role in tumor immunotherapy. J Hematol Oncol.
13(107)2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Sabado RL, Balan S and Bhardwaj N:
Dendritic cell-based immunotherapy. Cell Res. 27:74–95.
2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Huang L, Rong Y, Tang X, Yi K, Qi P, Hou
J, Liu W, He Y, Gao X, Yuan C and Wang F: Engineered exosomes as an
in situ DC-primed vaccine to boost antitumor immunity in breast
cancer. Mol Cancer. 21(45)2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z,
Qi H, Guo H and Yin H: Dendritic cell-derived exosomes elicit tumor
regression in autochthonous hepatocellular carcinoma mouse models.
J Hepatol. 67:739–748. 2017.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Wang X, He L, Huang X, Zhang S, Cao W, Che
F, Zhu Y and Dai J: Recent progress of exosomes in multiple
myeloma: Pathogenesis, diagnosis, prognosis and therapeutic
strategies. Cancers (Basel). 13(1635)2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Huang F, Wan J, Hao S, Deng X, Chen L and
Ma L: TGF-β1-silenced leukemia cell-derived exosomes target
dendritic cells to induce potent anti-leukemic immunity in a mouse
model. Cancer Immunol Immunother. 66:1321–1331. 2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Huang F, Li Z, Zhang W, Li J and Hao S:
Enhancing the anti-leukemia immunity of acute lymphocytic
leukemia-derived exosome-based vaccine by downregulation of PD-L1
expression. Cancer Immunol Immunother. 71:2197–2212.
2022.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Gabrusiewicz K, Li X, Wei J, Hashimoto Y,
Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, et al:
Glioblastoma stem cell-derived exosomes induce M2 macrophages and
PD-L1 expression on human monocytes. Oncoimmunology.
7(e1412909)2018.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Hu K, Gu Y, Lou L, Liu L, Hu Y, Wang B,
Luo Y, Shi J, Yu X and Huang H: Galectin-3 mediates bone marrow
microenvironment-induced drug resistance in acute leukemia cells
via Wnt/β-catenin signaling pathway. J Hematol Oncol.
8(1)2015.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Cheng YL, Huang WC, Chen CL, Tsai CC, Wang
CY, Chiu WH, Chen YL, Lin YS, Chang CF and Lin CF: Increased
Galectin-3 facilitates leukemia cell survival from apoptotic
stimuli. Biochem Biophys Res Commun. 412:334–340. 2011.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Fei F, Joo EJ, Tarighat SS, Schiffer I,
Paz H, Fabbri M, Abdel-Azim H, Groffen J and Heisterkamp N: B-cell
precursor acute lymphoblastic leukemia and stromal cells
communicate through Galectin-3. Oncotarget. 6:11378–11394.
2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Chen T, Zhang G, Kong L, Xu S, Wang Y and
Dong M: Leukemia-derived exosomes induced IL-8 production in bone
marrow stromal cells to protect the leukemia cells against
chemotherapy. Life Sci. 221:187–195. 2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Macanas-Pirard P, Broekhuizen R, González
A, Oyanadel C, Ernst D, García P, Montecinos VP, Court F, Ocqueteau
M, Ramirez P and Nervi B: Resistance of leukemia cells to
cytarabine chemotherapy is mediated by bone marrow stroma, involves
cell-surface equilibrative nucleoside transporter-1 removal and
correlates with patient outcome. Oncotarget. 8:23073–23086.
2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Daver N, Venugopal S and Ravandi F: FLT3
mutated acute myeloid leukemia: 2021 Treatment algorithm. Blood
Cancer J. 11(104)2021.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Daver N, Schlenk RF, Russell NH and Levis
MJ: Targeting FLT3 mutations in AML: Review of current knowledge
and evidence. Leukemia. 33:299–312. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Viola S, Traer E, Huan J, Hornick NI,
Tyner JW, Agarwal A, Loriaux M, Johnstone B and Kurre P:
Alterations in acute myeloid leukaemia bone marrow stromal cell
exosome content coincide with gains in tyrosine kinase inhibitor
resistance. Br J Haematol. 172:983–986. 2016.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Wu J, Zhang Y, Li X, Ren J, Chen L, Chen J
and Cao Y: Exosomes from bone marrow mesenchymal stem cells
decrease chemosensitivity of acute myeloid leukemia cells via
delivering miR-10a. Biochem Biophys Res Commun. 622:149–156.
2022.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Crompot E, Van Damme M, Pieters K,
Vermeersch M, Perez-Morga D, Mineur P, Maerevoet M, Meuleman N,
Bron D, Lagneaux L and Stamatopoulos B: Extracellular vesicles of
bone marrow stromal cells rescue chronic lymphocytic leukemia B
cells from apoptosis, enhance their migration and induce gene
expression modifications. Haematologica. 102:1594–1604.
2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Javidi-Sharifi N, Martinez J, English I,
Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DT V, Agarwal A,
Lopez C, Jorgens D, et al: FGF2-FGFR1 signaling regulates release
of leukemia-protective exosomes from bone marrow stromal cells.
Elife. 8(e40033)2019.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Shah CA, Bei L, Wang H, Platanias LC and
Eklund EA: The leukemia-associated Mll-Ell oncoprotein induces
fibroblast growth factor 2 (Fgf2)-dependent cytokine
hypersensitivity in myeloid progenitor cells. J Biol Chem.
288:32490–32505. 2013.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Li MY, Zhao C, Chen L, Yao FY, Zhong FM,
Chen Y, Xu S, Jiang JY, Yang YL, Min QH, et al: Quantitative
proteomic analysis of plasma exosomes to identify the candidate
biomarker of imatinib resistance in chronic myeloid leukemia
patients. Front Oncol. 11(779567)2021.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Chen X, Chen Y, Zhang M, Cheng H, Mai H,
Yi M, Xu H, Yuan X, Liu S and Wen F: HucMSC exosomes promoted
imatinib-induced apoptosis in K562-R cells via a
miR-145a-5p/USP6/GLS1 axis. Cell Death Dis. 13(92)2022.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Dong Y, Lin Y, Gao X, Zhao Y, Wan Z, Wang
H, Wei M, Chen X, Qin W, Yang G and Liu L: Targeted blocking of
miR328 lysosomal degradation with alkalized exosomes sensitizes the
chronic leukemia cells to imatinib. Appl Microbiol Biotechnol.
103:9569–9582. 2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Min QH, Wang XZ, Zhang J, Chen QG, Li SQ,
Liu XQ, Li J, Liu J, Yang WM, Jiang YH, et al: Exosomes derived
from imatinib-resistant chronic myeloid leukemia cells mediate a
horizontal transfer of drug-resistant trait by delivering miR-365.
Exp Cell Res. 362:386–393. 2018.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Liu Y, Song B, Wei Y, Chen F, Chi Y, Fan
H, Liu N, Li Z, Han Z and Ma F: Exosomes from mesenchymal stromal
cells enhance imatinib-induced apoptosis in human leukemia cells
via activation of caspase signaling pathway. Cytotherapy.
20:181–188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H,
Fang X and Zhang X: Exosomes as a new frontier of cancer liquid
biopsy. Mol Cancer. 21(56)2022.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo
X, Wei Q, Wang J, Xiong H, Chen C, Xu B, et al: Exosome: Emerging
biomarker in breast cancer. Oncotarget. 8:41717–41733.
2017.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Boyiadzis M and Whiteside TL:
Plasma-derived exosomes in acute myeloid leukemia for detection of
minimal residual disease: Are we ready? Expert Rev Mol Diagn.
16:623–629. 2016.PubMed/NCBI View Article : Google Scholar
|
|
101
|
An T, Qin S, Xu Y, Tang Y, Huang Y, Situ
B, Inal JM and Zheng L: Exosomes serve as tumour markers for
personalized diagnostics owing to their important role in cancer
metastasis. J Extracell Vesicles. 4(27522)2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Bobrie A, Colombo M, Raposo G and Théry C:
Exosome secretion: Molecular mechanisms and roles in immune
responses. Traffic. 12:1659–1668. 2011.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Tzoran I, Rebibo-Sabbah A, Brenner B and
Aharon A: Disease dynamics in patients with acute myeloid leukemia:
New biomarkers. Exp Hematol. 43:936–943. 2015.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Hornick NI, Huan J, Doron B, Goloviznina
NA, Lapidus J, Chang BH and Kurre P: Serum exosome MicroRNA as a
minimally-invasive early biomarker of AML. Sci Rep.
5(11295)2015.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Hong CS, Muller L, Whiteside TL and
Boyiadzis M: Plasma exosomes as markers of therapeutic response in
patients with acute myeloid leukemia. Front Immunol.
5(160)2014.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Li Q, Wu Y, Zhang Y, Sun H, Lu Z, Du K,
Fang S and Li W: miR-125b regulates cell progression in chronic
myeloid leukemia via targeting BAK1. Am J Transl Res. 8:447–459.
2016.PubMed/NCBI
|
|
107
|
Jiang L, Deng T, Wang D and Xiao Y:
Elevated serum exosomal miR-125b level as a potential marker for
poor prognosis in intermediate-risk acute myeloid leukemia. Acta
Haematol. 140:183–192. 2018.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Lin X, Ling Q, Lv Y, Ye W, Huang J, Li X,
Guo Q, Wang J, Li Z and Jin J: Plasma exosome-derived microRNA-532
as a novel predictor for acute myeloid leukemia. Cancer Biomark.
28:151–158. 2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Ferrajoli A, Shanafelt TD, Ivan C, Shimizu
M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, et
al: Prognostic value of miR-155 in individuals with monoclonal
B-cell lymphocytosis and patients with B chronic lymphocytic
leukemia. Blood. 122:1891–1899. 2013.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Stamatopoulos B, Van Damme M, Crompot E,
Dessars B, Housni HE, Mineur P, Meuleman N, Bron D and Lagneaux L:
Opposite prognostic significance of cellular and serum circulating
MicroRNA-150 in patients with chronic lymphocytic leukemia. Mol
Med. 21:123–133. 2015.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Okimoto RA and Van Etten RA: Navigating
the road toward optimal initial therapy for chronic myeloid
leukemia. Curr Opin Hematol. 18:89–97. 2011.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2020 Update on diagnosis, therapy and monitoring.
Am J Hematol. 95:691–709. 2020.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Bernardi S, Foroni C, Zanaglio C, Re F,
Polverelli N, Turra A, Morello E, Farina M, Cattina F, Gandolfi L,
et al: Feasibility of tumor-derived exosome enrichment in the
onco-hematology leukemic model of chronic myeloid leukemia. Int J
Mol Med. 44:2133–2144. 2019.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Kibria G, Ramos EK, Wan Y, Gius DR and Liu
H: Exosomes as a drug delivery system in cancer therapy: Potential
and challenges. Mol Pharm. 15:3625–3633. 2018.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Ha D, Yang N and Nadithe V: Exosomes as
therapeutic drug carriers and delivery vehicles across biological
membranes: Current perspectives and future challenges. Acta Pharm
Sin B. 6:287–296. 2016.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Bellavia D, Raimondo S, Calabrese G, Forte
S, Cristaldi M, Patinella A, Memeo L, Manno M, Raccosta S, Diana P,
et al: Interleukin 3-receptor targeted exosomes inhibit in vitro
and in vivo chronic myelogenous leukemia cell growth. Theranostics.
7:1333–1345. 2017.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Taverna S, Giallombardo M, Pucci M, Flugy
A, Manno M, Raccosta S, Rolfo C, De Leo G and Alessandro R:
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia
cells growth: A possible role for exosomal disposal of miR-21.
Oncotarget. 6:21918–21933. 2015.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Gu X, Erb U, Büchler MW and Zöller M:
Improved vaccine efficacy of tumor exosome compared to tumor lysate
loaded dendritic cells in mice. Int J Cancer. 136:E74–E84.
2015.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Cheng Q, Shi X and Zhang Y: Reprogramming
exosomes for immunotherapy. Methods Mol Biol. 2097:197–209.
2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Qiao L, Hu S, Huang K, Su T, Li Z,
Vandergriff A, Cores J, Dinh PU, Allen T, Shen D, et al: Tumor
cell-derived exosomes home to their cells of origin and can be used
as Trojan horses to deliver cancer drugs. Theranostics.
10:3474–3487. 2020.PubMed/NCBI View Article : Google Scholar
|
